Illumina's expansion comes after 16 years of working closely with the company's channel partner in India, Premas Life Sciences. Now with its own permanent ...
Bruker Corporation (Nasdaq: BRKR) and PhenomeX Inc. (Nasdaq: CELL) today announced that they have signed a definitive agreement for Bruker to acquire Pheno...
Australia's Monash University and American firm Moderna have announced the establishment of the Monash-Moderna Quantitative Pharmacology Accelerator (MMQPA...
Bioreactor and cell retention technology integration features a single direct control interface to simplify intensified seed train implementation. Custo...
Under the agreement, AGC Biologics will leverage its monoclonal antibody development and manufacturing experience to perform process transfer, process opti...
FDA also accepted the "safety first" staggered parallel clinical design of ZM008 combination arm with Pembrolizumab to benefit a wider range of patients wh...
Acquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for USD 3.2bn upfront Deal brings two phase 3 assets in d...
ODD is in addition to Three FDA Fast Track Designations Genprex expects to dose the first patient in the Acclaim-3...
GenScript Biotech, the world's leading life-science research tools and services provider, and T-MAXIMUM Biotech, a biotechnology company pioneering univers...
Reports Q2 2023 total revenues of $338M, above the prior guidance range, net loss of $261M and adjusted EBITDA of $56M Updates FY 2023 guidance and prov...
QIAGEN announced the U.S. Food and Drug Administration (FDA) approval of its therascreen PDGFRA RGQ PCR kit (therascreen PDGFRA kit). This companion diagn...
Agilent Technologies Inc. (NYSE: A) announced the opening of a new full-scale Integrated Biology Center located at Monash University in Malaysia...
Poseida is a clinical-stage biotechnology company dedicated to advancing a new class of cancer cell therapy and gene therapy products using genetic enginee...
Chikungunya vaccine candidate met all the co-primary endpoints of the Phase 3 study and was shown to be highly immunogenic in the majority of subjects 22...
© 2025 Biopharma Boardroom. All Rights Reserved.
